相似文献
1
Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
Clin Pharmacol Ther. 2008 Jan;83(1):77-85. doi: 10.1038/sj.clpt.6100230. Epub 2007 May 9.
2
Role of itraconazole metabolites in CYP3A4 inhibition.
Drug Metab Dispos. 2004 Oct;32(10):1121-31. doi: 10.1124/dmd.104.000315. Epub 2004 Jul 8.
3
Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
Drug Metab Dispos. 2006 Apr;34(4):583-90. doi: 10.1124/dmd.105.008508. Epub 2006 Jan 13.
4
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Theor Biol Med Model. 2007 Mar 26;4:13. doi: 10.1186/1742-4682-4-13.
5
Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats.
Drug Metab Dispos. 2008 Jun;36(6):1097-101. doi: 10.1124/dmd.108.020644. Epub 2008 Mar 13.
6
Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.
Clin Pharmacol Ther. 2010 Oct;88(4):499-505. doi: 10.1038/clpt.2010.119. Epub 2010 Aug 25.
7
Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Drug Metab Pharmacokinet. 2005 Feb;20(1):55-64. doi: 10.2133/dmpk.20.55.
8
Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole.
Clin Chim Acta. 2013 Jan 16;415:128-32. doi: 10.1016/j.cca.2012.10.028. Epub 2012 Oct 23.
9
In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A.
Xenobiotica. 2019 Jan;49(1):36-42. doi: 10.1080/00498254.2018.1425510. Epub 2018 Jan 22.
10
Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
Drug Metab Dispos. 2018 Oct;46(10):1420-1433. doi: 10.1124/dmd.118.081364. Epub 2018 Aug 1.
引用本文的文献
1
Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism.
Front Pharmacol. 2025 Apr 11;15:1505557. doi: 10.3389/fphar.2024.1505557. eCollection 2024.
2
Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion-The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm.
Pharmaceutics. 2025 Jan 31;17(2):179. doi: 10.3390/pharmaceutics17020179.
3
Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections.
Curr Drug Targets. 2025;26(3):203-220. doi: 10.2174/0113894501337502241015121015.
4
Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling.
CPT Pharmacometrics Syst Pharmacol. 2024 Oct;13(10):1771-1783. doi: 10.1002/psp4.13221. Epub 2024 Sep 2.
5
Effects of Itraconazole on Pharmacokinetics of Mitragynine and 7-Hydroxymitragynine in Healthy Volunteers.
ACS Pharmacol Transl Sci. 2024 Feb 20;7(3):823-833. doi: 10.1021/acsptsci.3c00335. eCollection 2024 Mar 8.
6
Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data.
AAPS J. 2023 Jun 21;25(4):62. doi: 10.1208/s12248-023-00828-z.
7
Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B.
Molecules. 2022 Oct 12;27(20):6815. doi: 10.3390/molecules27206815.
8
Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination.
Pharmaceutics. 2022 Mar 23;14(4):694. doi: 10.3390/pharmaceutics14040694.
9
How Science Is Driving Regulatory Guidances.
Methods Mol Biol. 2021;2342:595-629. doi: 10.1007/978-1-0716-1554-6_19.
10
Multienzyme Kinetics and Sequential Metabolism.
Methods Mol Biol. 2021;2342:89-112. doi: 10.1007/978-1-0716-1554-6_4.
本文引用的文献
1
Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations.
Biochemistry. 2006 May 23;45(20):6341-53. doi: 10.1021/bi0600042.
2
Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
Drug Metab Dispos. 2006 Apr;34(4):583-90. doi: 10.1124/dmd.105.008508. Epub 2006 Jan 13.
3
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.
J Pharmacol Exp Ther. 2005 Jul;314(1):180-90. doi: 10.1124/jpet.104.082826. Epub 2005 Mar 22.
4
Disposition of posaconazole following single-dose oral administration in healthy subjects.
Antimicrob Agents Chemother. 2004 Sep;48(9):3543-51. doi: 10.1128/AAC.48.9.3543-3551.2004.
5
Role of itraconazole metabolites in CYP3A4 inhibition.
Drug Metab Dispos. 2004 Oct;32(10):1121-31. doi: 10.1124/dmd.104.000315. Epub 2004 Jul 8.
6
Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method.
J Pharm Sci. 2004 Apr;93(4):847-54. doi: 10.1002/jps.20012.
7
Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation.
Pediatr Transplant. 2003 Dec;7(6):474-8. doi: 10.1046/j.1397-3142.2003.00103.x.
8
Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).
Drug Metab Dispos. 2004 Feb;32(2):267-71. doi: 10.1124/dmd.32.2.267.
9
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
Drug Metab Dispos. 2004 Feb;32(2):259-66. doi: 10.1124/dmd.32.2.259.
10
Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients.
Transplant Proc. 2003 Dec;35(8):2873-7. doi: 10.1016/j.transproceed.2003.10.058.
Zotero 插件